Novel therapeutic agents targeting the epidermal growth factor receptor (EGFR) have
improved outcomes for a subgroup of patients with colorectal, lung, head and neck, and …

The epidermal growth factor receptor (EGFR) is a growth factor receptor that induces cell
differentiation and proliferation upon activation through the binding of one of its ligands. The …

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase receptor that is
frequently expressed in epithelial tumors. The EGFR was the first receptor to be proposed as …

In recent years, the epidermal growth factor receptor (EGFR) has been recognized as a
central player and regulator of cancer cell proliferation, apoptosis and angiogenesis and …

Inhibition of the epidermal growth factor receptor as a target for cancer chemotherapy has
proven to be an effective treatment in both preclinical and clinical settings. Recent work has …

Aberrant expression of the epidermal growth factor receptor (EGFR) system has been
reported in a wide range of epithelial cancers. In some studies, this has also been …

The discovery of epidermal growth factor receptor (EGFR) mutations in never-smokers has
been the most relevant finding ever in non–small cell lung cancer. When patients whose …

Over the past 30 years, a relatively simple growth factor and its cognate receptor have
provided seminal insights into the understanding of the genetic basis of cancer, as well as …

Epidermal growth factor receptor (EGFR) inhibitors were among the first type of targeted
agents discovered in cancer and currently constitute the standard of care for a wide range of …

Epidermal growth factor receptor (EGFR), a receptor tyrosine kinase, is activated by ligand
binding, overexpression, or mutation. It is well known for its tyrosine kinase-dependent …